Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies

摘要

We reported that current assignment of HLA ‐ DQ is a barrier to organ allocation. Here we simulated the impact of incorporating HLA ‐ DQ antigens and antibodies as A/B and αβ allelic variants, respectively, on calculated panel reactive antibody ( cPRA ) and probability of finding potential compatible donors ( PCD ). A cohort of 1224 donors and 2075 sensitized candidates was analyzed using HLA ‐ DQ αβ allelic (study) versus serologic (current practice) nomenclature. A significant (p??10 ?4 ) decrease in cPRA was observed with higher impact for male versus female, and first transplant versus retransplant (p??10 ?4 ), affecting mostly patients with moderate cPRA (30–80%). Consequently, the number of patients qualifying for 100% cPRA points according to the United Network for Organ Sharing–Kidney Allocation System decreased by 37%. More critically, by using allelic versus serologic nomenclature for HLA ‐ DQ , the number of PCD s for all patients was increased, with male and first‐transplant patients showing a higher expansion compared with female and retransplants. Patients of blood group O showed the highest benefit. The goal of reporting unacceptable antigens is to improve accuracy of virtual crossmatching and increase the likelihood of finding immunologically compatible donors. Our simulation provides strong support for the need to re‐evaluate the use of allele typing and how HLA ‐ DQ antigens and antibodies are incorporated into allocation policies to ensure equity.